This is a prospective, multicenter, observational study to evaluate the effectiveness of Olmetec® or Olmetec Plus® on nocturnal blood pressure control in Korean patients with stage 1 hypertension. Patients receiving Olmetec-based therapy in routine clinical practice will be followed to assess changes in ambulatory blood pressure, including nocturnal blood pressure and blood pressure variability.
Adults aged ≥19 years
Patients diagnosed with stage 1 hypertension according to clinical guidelines
Patients who are newly prescribed Olmetec® or Olmetec Plus® in routine -clinical practice
Patients who are able to undergo ambulatory blood pressure monitoring (ABPM)
Patients with secondary hypertension
Patients with severe hypertension requiring immediate pharmacological i-ntervention
Patients with known hypersensitivity to olmesartan medoxomil, hydrochlorothiazide, or any component of the study drugs
Patients who are pregnant, planning to become pregnant, or breastfeeding
Patients with stage 1 hypertension in Korea who are newly prescribed Olmetec® or Olmetec Plus® according to routine clinical practice. Eligible patients are adults who meet the inclusion and exclusion criteria and are able to undergo ambulatory blood pressure monitoring (ABPM).
Cohort
Prospective
Not listed
Change in mean 24-hour systolic blood pressure
Change in mean 24-hour systolic blood pressure measured by ambulatory blood pressure monitoring (ABPM) from baseline to 12 weeks (up to 20 weeks).
Change in clinic systolic and diastolic blood pressure
Change in clinic systolic and diastolic blood pressure from baseline.
Responder rate
Proportion of patients achieving systolic blood pressure \<140 mmHg or a reduction of ≥20 mmHg from baseline.
Change in mean 24-hour diastolic blood pressure
Change in nocturnal systolic and diastolic blood pressure
Click on the lead sponsor to view all of their trials.
